ABL Bio Valuation

Is A298380 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A298380 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A298380 (₩33650) is trading above our estimate of fair value (₩3853.42)

Significantly Below Fair Value: A298380 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A298380?

Other financial metrics that can be useful for relative valuation.

A298380 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue51.5x
Enterprise Value/EBITDA-44.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does A298380's PS Ratio compare to its peers?

The above table shows the PS ratio for A298380 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average17.9x
A006280 GC Biopharma
1x8.8%₩1.6t
A214450 PharmaResearch
7.3x22.7%₩2.3t
A007390 NatureCellLtd
54.7xn/a₩1.6t
8.7x17.6%₩2.9t
A298380 ABL Bio
49.1x24.7%₩1.6t

Price-To-Sales vs Peers: A298380 is expensive based on its Price-To-Sales Ratio (49.1x) compared to the peer average (17.9x).


Price to Earnings Ratio vs Industry

How does A298380's PE Ratio compare vs other companies in the KR Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a67.7%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a67.7%
n/an/an/a
No more companies

Price-To-Sales vs Industry: A298380 is expensive based on its Price-To-Sales Ratio (49.1x) compared to the KR Biotechs industry average (9.2x).


Price to Sales Ratio vs Fair Ratio

What is A298380's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A298380 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio49.1x
Fair PS Ratio7.9x

Price-To-Sales vs Fair Ratio: A298380 is expensive based on its Price-To-Sales Ratio (49.1x) compared to the estimated Fair Price-To-Sales Ratio (7.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A298380 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩33,000.00
₩44,750.00
+35.6%
21.0%₩60,000.00₩37,000.00n/a4
Nov ’25₩35,850.00
₩44,750.00
+24.8%
21.0%₩60,000.00₩37,000.00n/a4
Oct ’25₩31,000.00
₩38,750.00
+25.0%
9.4%₩45,000.00₩36,000.00n/a4
Sep ’25₩34,600.00
₩38,750.00
+12.0%
9.4%₩45,000.00₩36,000.00n/a4
Aug ’25₩29,200.00
₩36,500.00
+25.0%
1.4%₩37,000.00₩36,000.00n/a4
Jul ’25₩24,450.00
₩36,666.67
+50.0%
1.3%₩37,000.00₩36,000.00n/a3
Jun ’25₩22,650.00
₩36,666.67
+61.9%
1.3%₩37,000.00₩36,000.00n/a3
May ’25₩26,000.00
₩36,666.67
+41.0%
1.3%₩37,000.00₩36,000.00n/a3
Apr ’25₩27,400.00
₩36,666.67
+33.8%
1.3%₩37,000.00₩36,000.00n/a3
Mar ’25₩22,800.00
₩36,500.00
+60.1%
1.4%₩37,000.00₩36,000.00n/a2
Feb ’25₩21,800.00
₩36,500.00
+67.4%
1.4%₩37,000.00₩36,000.00n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies